The Top Tech of 2016

CAR-T PRIMERThe hottest cancer therapy in the pipeline — chimeric antigen receptor therapy (CAR-T) — continued to mature in 2016 with its first FDA approval for blood cancer patients set to arrive this year.

What’s next in the world of CAR-T? A whole lot:

• Additional cancer and autoimmune disease indications in preclinical development.
• Added safety features.
• More affordable “off the shelf” versions of the technology.

Let’s first welcome 2017 by reviewing how this key therapeutic works; we will continue our discussion by covering the future of CAR-T in our next edition.

Read More